Endometrial carcinoma is still one of the most common malignant tumor of the female genital system in the most industrialized countries. Endometrial cancer is due to 3,9% of all female malignant tumors. The occurence of endometrial cancer varies with age. In 75% of all cases endometral carcinoma tipically occurs in postmenopausal women, with the highest incidence between 50 and 59 year. The high frequence of endometrial carcinoma in younger age is also found in women with ovarian estrogen-secreting tumors. About 10% of all endometrial carcinomas also in association with a genetic predisposition, but the most cases of endometrial carcinomas are sporadic. The most important prognostic factors for endometral carcinomas are: clinical stage, age, histopathological type and grade, as wel as hormonal receptors. Younger nulliparous women with early detected well-diferentiated endometrial carcinoma are usually treated by high doses of progesterone. Older women with endometrial carcinoma are usually treated by hysterectomy. Administration of postoperative radiation and chemiotherapy depends on clinical stage.
Scholten AN, Creutzberg CL, Noordijk EM, Smit VT. Long-term outcome in endometrial carcinoma favors a two- instead of a three-tiered grading system. Int J Radiat Oncol Biol Phys. 52(4):1067–74.
2.
Weir HK, Sloan M, Kreiger N. The relationship between cigarette smoking and the risk of endometrial neoplasms. Int J Epidemiol. 23:261–6.
3.
Stefansson I, Akslen LA, MacDonald N, Ryan A, Das S, Jacobs IJ, et al. Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study.
4.
Cullinan JA, Fleischer AC, Kepple DM, Arnold AL. Sonohysterography: a technique for endometrial evaluation. Radiographics. 15:501–14.
5.
Kerpsack JT, Finan MA, Kline RC. Correlation between endometrial cells on Papanicolaou smear and endometrial carcinoma. South Med J. Aug;91(8):749-52.
6.
Clark TJ, Mann CH, Shah N, Khan KS, Song F, Gupta JK. Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic quantitative review. BJOG. Mar;109(3):313-21.
Ronnett BM, Zaino RJ, Ellenson LH, Kurman RJ. Endometrial carcinoma. In: Bluestein’s Pathology of the Female Genital Tract. p. 501–59.
9.
Goff BA, Kato D, Schmidt RA, Ek M, Ferry JA, Muntz HG, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol. 54(3):26–48.
10.
Mariani A, Webb MJ, Keeney GL, Lesnick TG, Podratz KC. Surgical stage I endometrial cancer: predictors of distant failure and death. Gynecol Oncol. 87(3):274–80.
11.
Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 40(1):55–65.
12.
Jain MG, Howe GR, Rohan TE. Nutritional factors and endometrial cancer in Ontario, Canada. Cancer Control. 7:288–96.
13.
Aoki Y, Watanabe M, Amikura T, Obata H, Sekine M, Yahata T, et al. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer. Gynecol Oncol. 94(2):33–9.
14.
DiSaia PJ, Creasman WT, Boronow RC, Blessing JA. Risk factors and recurrent patterns in Stage I endometrial cancer. Am J Obstet Gynecol. 151(8):1009–15.
15.
Nelson G, Randall M, Sutton G, Moore D, Hurteau J, Look K. FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy. Gynecol Oncol. 75(2):211–4.
16.
Schink JC, Rademaker AW, Miller DS, Lurain. Tumor size in endometrial cancer. Cancer. 67(11):279–84.
17.
Creasman WT, KS M, Barton TK, KS M. Clinical correlates of estrogen- and progesterone-binding proteins in human endometrial adenocarcinoma. Obstet Gynecol. 55(3):363–70.
18.
Herbolsheimer M, Rotte K. Cancer of the endometrium. In: Radiation Oncology of Gynecological Cancers. p. 241–96.
19.
Aalders JG, Abeler V, Kolstad P. Clinical (stage III) as compared to subclinical intrapelvic extrauterine tumor spread in endometrial carcinoma: a clinical and histopathological study of 175 patients. Gynecol Oncol. 17(1):64–74.
20.
Polyzos NP, Pavlidis N, Paraskevaidis E, Ioannidis JP. Randomized evidence on chemotherapy and hormonal therapy regimens for advanced endometrial cancer: an overview of survival data. Eur J Cancer. 42(3):319–26.
Suriano KA, McHale M, McLaren CE, Li KT, Re A, DiSaia PJ. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol. Apr;97(4):555-60.
23.
Surveillance E, Results E. Program. In: SEER Database: Incidence - SEER 9 Regs Public-Use.
24.
Levi F, Lucchini F, Negri E, Boyle P, Vecchia C. Cancer mortality in Europe, 1990-1994, and an overview of trends from 1955 to 1994. Eur J Cancer. Oct;35(10):1477-516.
25.
Mack TM, Cozen W, Quinn MA. Epidemiology of cancer of the endometrium, ovary, vulva and vagina. Gynecologic Oncology. :31–54.
26.
Lj MD, S Ž, I R. Epidemiology of malignant disease of female genital organs in Central Serbia.
27.
Weber AM, Belinson JL, Piedmonte MR. Risk factors for endometrial hyperplasia and cancer among women with abnormal bleeding. Obstet Gynecol. 93:594–8.
28.
Mogren I, Stenlund H, Hogberg U. Long-term impact of reproductive factors on the risk of cervical, endometrial, ovarian and breast cancer. Acta Oncol. 40:849–54.
29.
Tscherne G. Female genital tract malignancies during puberty. Uterine and cervical malignancies. Ann N Y Acad Sci.
30.
Doorn HC, BC O, M JD, RF K, FP D, BW M. The relation between age, time since menopause, and endometrial cancer in women with postmenopausal bleeding. Int J Gynecol Cancer.
31.
Benjamin F, Toles AW, Seltzer VL, Deutsch S. Excessive estradiol secretion in polycystic ovarian disease. Am J Obstet Gynecol. (v;169(5):1223-6).
32.
Jemal A, Siegel R, Ward E. Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
33.
Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS. Gynecologic Oncology Group Study. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study.
34.
Kumle M, Alsaker E, Lund E. Use of oral contraceptives and risk of cancer, a cohort study. Tidsskr Nor Laegeforen. 12;123(12):1653-6.
35.
Vecchia C. Oral contraceptives and cancer. Minerva Ginecol.
36.
Maxwell GL, Schildkraut JM, Calingaert B, Risinger JI, Dainty L, Marchbanks PA, et al. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol.
37.
Grady D, Ernster VL. Endometrial cancer. In: Cancer Epidemiology and Prevention. p. 1058–89.
38.
Silverberg SG, Haukkamaa M, Arko H, Nilsson CG, Luukkainen T. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int J Gynecol Pathol. 5:235–41.
39.
Gardner FJE, Konje JC, Abrams KR, Brown LJR, Khanna S. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomized controlled study. Lancet. 356:1711–7.
40.
Soliman PT, RL B, Wilson EB, Boyd-Rogers S, Schmeler KM, Milam MR, et al. Limited public knowledge of obesity and endometrial cancer risk: what women know. Obstet Gynecol. Oct;112(4):835-42.
41.
Lane G. Obesity and gynaecological cancer. Menopause Int. Mar;14(1):33-7.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
